|
|
|
|
|
Click Here to return To Results
|
|
|
|
Two prior double-blind, placebo-controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, o nset, and durability of any effect of GA on disease activity monitored with magnetic resonance imaging (MRI) in patients with RRMS. Treatment with GA showed a significant reduction in the total number of enhancing lesions compared with placebo (-10.8, 95 % confidence interval -18.0 to -3.7; p = 0.003). Consistent differences favoring treatment with GA were seen for almost all secondary end points examined: number of new enhancing lesions (p < 0.003), monthly change in the volume of enhancing lesions (p = 0.01), and change in volume (p = 0.006) and number of new lesions on T2-weighted images (p < 0.003). The relapse rate was also significantly reduced by 33% for GA-treated patients (p = 0.012). All effects increased over time. Glatiramer acetate signif icantly reduced MRI-measured disease activity and burden. |
|
(click to filter results - removes previous filter)
cop 1
gadolinium
MRI
MRI,abnormal
MRI,contrast enhanced
MRI,demyelinating disease
MRI,serial
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
treatment of neurologic disorder
|
Click Here to return To Results
|
|